Abstracts tagged "Lupus nephritis"

Abstract Number: 0930 • ACR Convergence 2023
Genetic Risk Profiles of Patients with Lupus Nephritis to Identify Those at Risk for Kidney Deterioration and Eventual Damage
Aastha Khatiwada¹, bethany wolf², Isabelle Ayoub³, Juan Mejia-Vilet⁴, Ana Malvar⁵, Carl Langefeld⁶, Brad Rovin³, Jim Oates² and Betty Tsao², ¹National Jewish Health, Denver, CO, ²Medical University of South Carolina, Charleston, SC, ³Ohio State University, Columbus, OH, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁵Hospital Fernandez, Buenos Aires, Argentina, ⁶Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: Many genetic variants are associated with lupus nephritis (LN). Yet, the majority of associated variants have a small effect size; hence, they convey small…
Abstract Number: 1493 • ACR Convergence 2023
Novel BCMA-CD19 Compound CAR-T (cCAR) Targets B Cells and Plasma Cells Achieving Immune Reset and Eliminates All Autoantibodies in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients Resulting in Long-Term, Medication-Free Remission
Yong Yuan¹, Shanzhi He¹, Wenli Zhang², Hongyu Zhang², Vincent DeStefano³, Masayuki Wada³, Kevin Pinz³, Greg Deener³, Yu Ma⁴, Min Wang¹, Fugui Li¹, Ming Hong¹, Chanjuan Zou¹, Mingxia Wang¹, Ling Ding¹, Yingwen Liang¹, Yupo Ma³ and Weijia Wang¹, ¹Zhongshan People’s Hospital, Zhongshan, China, ²Peking University Shenzhen Hospital, Shenzhen, China, ³iCell Gene Therapeutics Inc., Stony Brook, NY, ⁴iCAR Bio Therapeutics Ltd, Zhongshan, China
Background/Purpose: Evaluate cCAR safety in SLE, LN and autoimmune conditions. Determine whether a single dose eliminates autoantibodies with well tolerated long-term, medication-free remission in open…
Abstract Number: 1705 • ACR Convergence 2023
Reduced DNASE1L3 Activity and Increased Anti-NET Protective Antibodies Contributes to Accumulation of Neutrophil Extracellular Traps in Pediatric SLE Patients
Betsy Barnes¹, Lydia Thomas², Jenna Battaglia Battaglia³, Kim Simpfendorfer³, Joyce Hui-Yuen⁴, Vinay Sharma⁵ and Bharati Matta⁶, ¹Northwell Health, Manhasset, NY, ²Northwell Health - Cohen Children's Medical Center, Lake Success, NY, ³Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁴North Shore LIJ Health System, Great Neck, NY, ⁵Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India, ⁶The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY and Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, NY
Background/Purpose: Pediatric systemic lupus erythematosus (pSLE) is a multisystemic chronic autoimmune disease with high renal involvement. In SLE, neutrophil extracellular traps (NETs) are considered a…
Abstract Number: 2427 • ACR Convergence 2023
Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis
Alessandra Ida Celia¹, Xiaoping Yang², Hana Minsky², Silvia Malvica², Michelle Petri³, the Accelerating Medicines Partnership in RA/SLE⁴, Avi Rosenberg⁵ and Andrea Fava², ¹John Hopkins University of Medicine, Rome, Italy, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴Multiple, Multiple, ⁵Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: As part of the Accelerating Medicines Partnership (AMP), we discovered that urinary PR3, a neutrophil degranulation product, is associated with histological activity, indicating the…
Abstract Number: 0179 • ACR Convergence 2023
Social Disparities and Pathology Markers at Lupus Nephritis Diagnosis Predict Worse Kidney Outcomes
Shivani Garg¹, Brad Astor², Amish Raval², S. Sam Lim³, Weixiong Zhong², Sarah Panzer², Brad Rovin⁴ and Christie M. Bartels², ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, WI, ³Emory University, Atlanta, GA, ⁴Ohio State University, Columbus, OH
Background/Purpose: At diagnosis, a typical 30-year-old with lupus nephritis (LN) already has 10-fold higher chronic kidney disease (CKD) risk than peers and LN is a…
Abstract Number: 0849 • ACR Convergence 2023
Multiplex Profiling and Machine Learning Reveal Distinct Signatures of Circulating Cytokines Associated with Autoantibody Profiles and Disease Severity in Systemic Lupus Erythematosus
Sarit Pattanaik¹, Ratnadeep Mukherjee², Rina Tripathy³, Birendra Prusty⁴, Balachandran Ravindran⁵ and Bidyut Das⁶, ¹SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, India, ²Norwegian Institute of Public Health, Oslo, Norway, ³Sardar Vallabhbhai Patel Post Graduate Institute of Pediatrics, Cuttack, India, ⁴Fisheries & Animal Resources Development Department, Phulbani, India, ⁵Institute of Life Sciences, Bhubaneswar, India, ⁶SCB medical college, Cuttack, India
Background/Purpose: SLE is one of the leading causes of death in young females suffering from autoimmune disorders. Nephritis, afflicts 60-70% of patients which contribute significantly…
Abstract Number: 0933 • ACR Convergence 2023
The ‘Sweet’ in Lupus – IgG Glycosylation in Lupus Nephritis
Rhea Bhargava¹, Rohit Upadhyay², Scott Wenderfer³, Jing Chen² and George Tsokos⁴, ¹Tulane University, New Orleans, LA, ²Tulane University School of Medicine, New Orleans, LA, ³University of British Columbia, Vancouver, BC, Canada, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Lupus nephritis (LN) occurs in 50% of patients with systemic lupus erythematosus (SLE) for which we lack biomarkers, and an understanding of its pathogenesis.…
Abstract Number: 1495 • ACR Convergence 2023
Deep Serological Profiling of SLE Patients Treated with anti-CD19 CAR T Cells
Samik Basu¹, Daniel Nunez¹, Darshil Patel¹, Jenell Volkov¹, Zachary Vorndran¹, Steven Wong¹, Andreas Mackensen² and Georg Schett³, ¹Cabaletta Bio, Philadelphia, PA, ²Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a ground-breaking emerging treatment modality for severe refractory systemic lupus erythematosus (SLE) and has shown…
Abstract Number: 2017 • ACR Convergence 2023
Lupus Nephritis Is Strongly Associated with Low Bone Mineral Density and Osteoporosis in Patients with Systemic Lupus Erythematosus
Edgar Wiebe¹, Elisa Schilling², Dörte Huscher³, Andriko Palmowski⁴, Zhivana Boyadzhieva⁵, Sandra Hermann¹, Burkhard Muche¹, Tobias Alexander⁶, Falk Hiepe⁵ and Frank Buttgereit¹, ¹Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany, ³Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁶Charité Universiätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for osteoporosis and fragility fractures. This risk is mediated by a variety of factors…
Abstract Number: 2443 • ACR Convergence 2023
Blockade of OX40/OX40L Signaling Using anti-OX40L Ameliorates Systemic Lupus Erythematosus
Junpeng Zhao¹, Liming Li¹, Xiwei Feng¹, Huiqi Yin¹ and Qianjin Lu², ¹Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China, ²Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Changsha, China
Background/Purpose: Genetic variations in the OX40 ligand (OX40L) locus have been implicated in the susceptibility to systemic lupus erythematosus (SLE). Notably, the blockade of OX40L…
Abstract Number: 005 • 2023 Pediatric Rheumatology Symposium
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study
Emily Zhang¹, Gabrielle Alonzi¹, Madeline Hlobik¹, Esra Meidan¹, Mindy Lo¹, Olha Halyabar², Melissa Hazen¹, Ezra Cohen³, Lauren Henderson¹, Siobhan Case⁴, Margaret Chang¹, Camille Frank¹, Ankana Daga¹, Jonathan Hausmann⁵, Ahmad Bakhsh¹, Liyoung Kim¹, Daniel Ibanez¹, Holly Wobma¹, Mia Chandler⁶, Fatma Dedeoglu¹, Robert Sundel¹, Peter Nigrovic¹, Karen Costenbader⁷, Mary Beth Son¹ and Joyce Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Children's Hospital/Boston Medical Center, Boston, MA, ³Boston Medical Center, Boston, MA, ⁴Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁵Boston Children's Hospital / Massachusetts General Hospital, Boston, MA, ⁶Boston Children's Hospital; Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: The morbidity of chronic glucocorticoid (GC) use is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The newly developed pediatric glucocorticoid…
Abstract Number: 012 • 2023 Pediatric Rheumatology Symposium
Thrombotic Microangiopathic Changes in Kidney Biopsies of Childhood-Onset Systemic Lupus Erythematous Patients with and Without Severe Hematologic Disturbances
Cathy Tsin¹, Megan Troxell¹, Vivek Charu¹, Rufei Lu² and Joyce Hsu³, ¹Stanford University, Palo Alto, CA, ²UCSF, San Francisco, CA, ³Stanford Medicine, Children's Health, Palo Alto, CA
Background/Purpose: Outcomes for pediatric patients with lupus nephritis (LN) remain suboptimal. LN may present with thrombotic microangiopathy (TMA) seen on kidney biopsy. Childhood-onset SLE patients…
Abstract Number: 047 • 2023 Pediatric Rheumatology Symposium
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹, Kelly Rouster-Stevens¹⁰, Aliese Sarkissian¹¹, Julia Shalen¹², William Soulsby¹³, Marinka Twilt¹⁴, Eveline Wu¹⁵, Laura Lewandowski¹⁶, Scott Wenderfer¹⁷ and Jennifer Cooper¹⁸, ¹University of Michigan, Ann Arbor, MI, ²Duke University, Durham, NC, ³University of Colorado, Denver, CO, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵Akron Children's Hospital, Akron, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹¹UNC- Chapel Hill, Durham, NC, ¹²Johns Hopkins University, Baltimore, MD, ¹³University of California, San Francisco, San Francisco, CA, ¹⁴Alberta Children's Hospital, Calgary, AB, Canada, ¹⁵UNC Chapel Hill, Chapel Hill, NC, ¹⁶NIAMS, NIH, Bethesda, MD, ¹⁷British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁸University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
Abstract Number: 050 • 2023 Pediatric Rheumatology Symposium
Predictive Value of the 2019 EULAR/ACR SLE Criteria’s Extra-Renal Domains to Renal Response One Year After Treatment in a Pediatric Lupus Nephritis Cohort
Sara Patrizi¹, Megha Tandel², Derek Boothroyd² and Joyce Hsu¹, ¹Stanford Medicine, Children's Health, Palo Alto, CA, ²Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: In 2019, new classification criteria for SLE were developed by the EULAR/ACR. Prior research in adult lupus cohorts found a positive correlation between high…
Abstract Number: 0323 • ACR Convergence 2022
Identifying Distinct Phenotypes of Patients with Juvenile Systemic Lupus Erythematosus: Results from a Cluster Analysis by the Egyptian College of Rheumatology (ECR) Study Group
Nevin Hammam¹, Mohamed Bakrey Mahmoud², Aly Bakhiet³, Rasha El Owaidy⁴, Hend Abdel Nabi⁵, Ahmed M Elsaman⁶, Iman Khalifa⁷, Abeer M NourEl-Din⁸, Rawhya R ElShereef⁹, Eman Hassan¹⁰, Faten Ismail⁹, Iman I El-Gazzar¹¹, Abdelhafeez Moshrif¹², Noha M Khalil¹³, Marwa A Amer¹⁴, Hanan M Fathy¹⁵, Nancy Abdel Salam¹⁵, Samar Tharwat¹⁶, Mervat I Abd Elazeem¹⁷, Hanan M Fathi¹⁸ and Tamer A Gheita¹¹, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, ²Higher Institute for Computer Science and Information Systems, 6th of October City, Cairo, Egypt, ³Higher Institute for Computer Science and Information Systems, 6th of October City, Assiut, Egypt, ⁴Pediatric Allergy, Immunology and Rheumatology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt, ⁵Pediatrics Department, Rheumatology and Nephrology Unit, Tanta University, Gharbia, Egypt, ⁶Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ⁷Pediatrics Department, Rheumatology and Nephrology Unit, Helwan University, Cairo, Egypt, ⁸Pediatrics Department, National Research Centre (NRC), Cairo, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, ¹⁰Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt, ¹¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹²Rheumatology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt, ¹³Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁴Rheumatology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt, ¹⁵Pediatrics Department, Rheumatology and Nephrology Unit, Alexandria University, Alexandria, Egypt, ¹⁶Internal Medicine, Rheumatology Unit, Mansoura University, Dakahlia, Egypt, Dakahlia, Egypt, ¹⁷Rheumatology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, ¹⁸Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt
Background/Purpose: Juvenile systemic lupus erythematosus (J-SLE) is a complex autoimmune disease characterized by a great heterogeneity in organs involvement. A better understanding of the organ…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].